Loading...
Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Author Verified
RCT
ACE Report #2828
Ace Report Cover Pediatric Orthopaedics

Juvenile RA: Fewer disease flares with Adalimumab (TNF Antibody)


Study Type:Therapy
OE Level Evidence:2
Journal Level of Evidence:N/A

Adalimumab with or without Methotrexate in Juvenile Rheumatoid Arthritis

N Engl J Med. 2008 Aug 21;359(8):810-20

Contributing Authors: DJ Lovell N Ruperto S Goodman A Reiff L Jung K Jarosova D Nemcova R Mouy C Sandborg J Bohnsack D Elewaut I Foeldvari V Gerloni J Rovensky K Minden RK Vehe LW Weiner G Horneff HI Huppertz NY Olson JR Medich R Carcereri-De-Prati McIlra

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here

Synopsis

This was a three part study designed to assess the effectiveness of Adalimumab, a fully human monoclonal anti-TNF antibody, in the treatment of juvenile rheumatoid arthritis. The study consisted of an open-label lead-in phase (where patients were stratified according to methotrexate use), a double-blind withdrawal phase (following the 16 week lead-in phase, patients with an ACR Pedi 30 response we...

CME Image

Continuing Medical Education Credits

You could be earning 0.5 CME credits for each report you read.

LEARN MORE

Please Login or Join to leave comments.